Karen Ruth Rabin MD PhD
Professor, Pediatrics, Baylor College of Medicine
Join to View Full Profile
1825 4th StSan Francisco, CA 94143
Phone+1 415-476-3831
Fax+1 415-502-4372
Dr. Rabin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Karen Rabin is a medical professional based in Houston, TX, specializing in Pediatric Hematology & Oncology. She completed her Pediatric Hematology/Oncology fellowship at Lucile Packard Children's Hospital/Stanford University School of Medicine in 2004, following the completion of her Pediatrics residency at the University of California San Francisco School of Medicine in 2001. Dr. Rabin is Director of the Leukemia Program at Texas Children's Cancer Center and has significant experience in hematologic malignancies, particularly acute lymphoblastic leukemia (ALL). She has contributed to pediatric oncology research through numerous publications and has been involved in multiple clinical trials focused on therapies for childhood ALL.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
University of California (San Francisco)Residency, Pediatrics, 1998 - 2001- University of California San Francisco School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2025 - 2027
TX State Medical License 2006 - 2025
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
Publications & Presentations
PubMed
- Structural birth defects and leukemia risk in children with Down syndrome.Ching-Ju Hsu, Jeremy M Schraw, Sonja A Rasmussen, Tiffany M Chambers, Tania A Desrosiers
Scientific Reports. 2025-12-11 - An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy.Emily J Mason, Anna M Crain, Michael E Scheurer, Philip J Lupo, Karen R Rabin
Blood Advances. 2025-11-25 - The impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children.Jalen Langie, Tsz Fung Chan, Wenjian Yang, Alice Y Kang, Libby Morimoto
HGG Advances. 2025-10-25
Abstracts/Posters
- Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic ...Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Genomic Landscape of Childhood Acute Lymphoblastic LeukemiaKaren R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Pa...Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024
Press Mentions
Dasatinib Superior to Imatinib in Pediatric ALLJanuary 16th, 2020
Novel Approach Identifies Factors Linked to Poor Treatment Outcomes in Acute Lymphoblastic LeukemiaOctober 24th, 2019
Dasatinib Beats Imatinib in Childhood LeukemiaMarch 14th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
